Luis Oliverio Ambriz Garcia/X
Aug 27, 2026, 07:19
Luis Oliverio Ambriz Garcia: ASH 2026 Guidelines – What’s New in ITP?
Luis Oliverio Ambriz Garcia, Doctor, Specialist in Internal Medicine at HRAEB, Chief Executive Officer of Memodi, shared a post on X:
“The new American Society of Hematology (ASH, 2026) guidelines for Immune Thrombocytopenia.
Some key points and changes:
- First-line therapy: no longer steroids alone. Rituximab plus steroid or Thrombopoietin Receptor Agonists (TPO-RAs – such as Eltrombopag) plus steroid are suggested.
- Second-line therapy: Thrombopoietin Receptor Agonists (TPO-RAs). Order: TPO-RA then rituximab, then BTKi/MMF/SYKi, then azathioprine.
- Splenectomy: defer for greater than or equal to 1 year, vaccinate greater than or equal to 2 weeks prior, annual follow-up.
- Dosage: steroids for less than or equal to 6 weeks always; dexa 40 mg for 4 days (1–3 cycles) or prednisone 0.5–2 mg/kg/day; rituximab 375 mg/m² for 4 weeks.”
Stay updated with Hemostasis Today.
-
Aug 27, 2026, 11:08Sunisha Arora: New EBMT Recommendations Transform the Approach to HSCT in Thalassemia
-
Aug 27, 2026, 10:51Seema Dawood: A Layered Approach to Identifying Thalassemia in the Laboratory
-
Aug 27, 2026, 10:44Ed Smith: Vitalant Expands Hemophilia Center Team With New Career Opportunities
-
Aug 27, 2026, 10:43FDA Expands Hympavzi Approval to Children and Patients With Hemophilia A or B With Inhibitor
-
Aug 27, 2026, 10:28Narat Srivali: Exploring the Link Between Perioperative Corticosteroids and VTE Risk
-
Aug 27, 2026, 10:19Vincent Poher: Clinical Validation of Rapid Whole-Blood Fibrinogen Measurement
-
Aug 27, 2026, 07:49Denis Oduor: Bringing Blood Closer – Strengthening Kenya’s Response to PPH
-
Aug 27, 2026, 06:58Priyam Bordoloi: The Biological Advantage of Two X Chromosomes
-
Aug 27, 2026, 00:14Join EHA ReCon 2027 in Malta – Explore RNA Biology to Therapeutics